Jun 6, 2017
As it is often necessary to structure creative deals with deferred and/or ongoing value delivered to the seller, an important but frequently overlooked component of the deal process is to position your company as the ideal partner for the acquired asset. Recently, the...
May 31, 2017
Fresh off Memorial Day Weekend, I had to face the reality that summer is here! When the kids are out of school, the regular schedules that we have enjoyed throughout the year become replaced by a multitude of summer camps, travels, and family fun. But as we know,...
Mar 31, 2011
Nine years ago while I was working at a bulge bracket investment bank, I did an analysis (a pitch mind you) for a big biotech company to acquire Cephalon. I can’t tell you how many all-nighters I pulled working on this pitch. It included an overview of Cephalon and...
Mar 24, 2010
Biotech business development is out of whack! Something needs to be done fast or the best, brightest, and most experienced will leave their companies. Below is an example of what is wrong with biotech BD and what can be done to fix it. Suppose senior investment...
Feb 7, 2010
Today I listened to a very interesting, albeit brief, discussion about pre-negotiating the exit before the initial investment at the Venture Panel at the 2010 Wharton Health Care Business Conference. The moderator asked about structured transactions where the upside...
